Home
HelpTest Code MMLRG Antimicrobial Susceptibility, Acid-Fast Bacilli, Rapidly Growing, Varies
Infectious
Reporting Name
Susc, AFB, Rapidly GrowingUseful For
Determination of susceptibility of rapidly growing mycobacteria to the antimicrobial agents on the test panel
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
VariesAdditional Testing Requirements
If organism identification is not provided, CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies must also be ordered and will be charged separately.
Shipping Instructions
1. For shipping information see Infectious Specimen Shipping Guidelines
2. Place specimen in a large infectious container and label as an etiologic agent/infectious substance.
Necessary Information
1. Specimen source is required.
2. Organism identification is required unless either CTB / Mycobacteria and Nocardia Culture, Varies or CTBID / Culture Referred for Identification, Mycobacterium and Nocardia, Varies is also ordered.
3. Identification to the species level is required for Mycobacterium species for the correct antimicrobial susceptibility drug panel to be selected. Identification to the genus level is sufficient for Nocardia species and other aerobic actinomycetes (eg, Gordonia species, Rhodococcus species).
Specimen Required
Specimen Type: Organism
Supplies: Infectious Container, Large (T146)
Container/Tube: Middlebrook 7H10 agar slant or other appropriate media
Specimen Volume: Pure isolate
Collection Instructions: Organism must be in pure culture, actively growing.
Specimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient (preferred) | ||
| Refrigerated | |||
Special Instructions
Reference Values
Interpretive criteria and reporting guidelines are followed using the Clinical Laboratory Standards Institute (CLSI) M24S document.
Day(s) Performed
Monday through Sunday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87186
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MMLRG | Susc, AFB, Rapidly Growing | 29579-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| MMLRG | Susc, AFB, Rapidly Growing | 29579-0 |
Additional Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SRG | Susceptibility Rapid Grower | No, (Bill Only) | Yes |
Testing Algorithm
When this test is ordered, rapid grower susceptibility will be performed at an additional charge.
Clinical Information
There are more than 100 species of rapidly growing mycobacteria and many are significant human pathogens (eg, Mycobacterium abscessus, Mycobacterium chelonae, Mycobacterium fortuitum). Rapidly growing mycobacteria cause a variety of infections including pulmonary infections, skin and soft tissue infections, and disseminated disease. Antimicrobial susceptibility testing of clinically significant rapidly growing mycobacteria is important to help guide patient care.
Antimicrobials tested in this assay are amikacin, cefoxitin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, imipenem, linezolid, moxifloxacin, tigecycline, tobramycin, and trimethoprim/sulfamethoxazole.
Interpretation
Results are reported as the minimum inhibitory concentration in micrograms/mL. Interpretive criteria (susceptible, intermediate, or resistant) are reported according the Clinical and Laboratory Standards Institute guidelines.
Clinical Reference
1. Brown-Elliott BA, Pilley JV. Rapidly growing mycobacteria. Microbiol Spectr. 2017;5(1):1-19
2. Apiwattankul N, Flynn PM, Hayden RT, Adderson EE. Infections caused by rapidly growing mycobacteria spp in children and adolescents with cancer. J Pediatric Infect Dis Soc. 2015;4(2):104-113
3. Kasperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med. 2015;36(1):67-78
Method Description
The method employed in this assay is broth microtiter dilution using a commercially available RAPMYCO2 plate. Antimicrobials included in the assay are tested according to CLSI guidelines.(Clinical and Laboratory Standards Institute [CLSI]. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI standard M24. Clinical and Laboratory Standards Institute [CLSI]. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. CLSI supplement M24S)
Report Available
12 to 28 daysSpecimen Retention Time
2 yearsReject Due To
| Agar plate | Reject |
Method Name
Minimum Inhibitory Concentration (MIC) by Microtiter Broth Dilution Method
Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.